RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium
RenovoRx, an innovator in targeted cancer therapy, today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment. In one presentation, preliminary data from the ongoing Phase III TIGeR-PaC Clinical Trial was used to investigate incidence of sepsis in pancreatic cancer patients. In the second presentation, data regarding resection rates in patients with Locally Advanced Pancreatic Cancer (LAPC) undergoing IV gemcitabine + nab-paclitaxel treatment regimens as part of the induction phase of the TIGeR-PaC study was shared. The TIGeR-PaC trial’s primary goal is to determine whether its proprietary Trans-Arterial Micro-Perfusion (TAMP®) procedure utilizing intra-arterial gemcitabine can reduce the chance of cancer spreading and extend survival while improving quality of life for pancreatic cancer patients.
RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium
RenovoRx today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment.